Literature DB >> 21481395

Plasma phospholipid transfer protein activity is independently determined by obesity and insulin resistance in non-diabetic subjects.

Rindert de Vries1, Paul J W H Kappelle, Geesje M Dallinga-Thie, Robin P F Dullaart.   

Abstract

BACKGROUND: Phospholipid transfer protein (PLTP) is an emerging cardio-metabolic risk factor which is intricately involved in lipoprotein metabolism. Elevated plasma PLTP activity levels are reported in obesity and diabetes mellitus, but the relative contributions of obesity and insulin resistance to plasma PLTP activity remain unclear. We tested whether plasma PLTP activity is independently related to (central) obesity and insulin resistance in non-diabetic subjects.
METHODS: The relationships of plasma PLTP activity levels (phospholipid vesicles-HDL system) with waist circumference, waist/hip ratio, body mass index (BMI) and insulin resistance (homeostasis model assessment (HOMA(ir))) were determined in 313 non-diabetic subjects (273 men).
RESULTS: PLTP activity was higher in 67 subjects with enlarged waist circumference (NCEP-ATP-III criteria; 102 ± 11 AU) compared to 246 subjects with normal waist (98 ± 11 AU, P=0.027). In univariate analysis PLTP activity correlated positively with waist (r=0.188), waist/hip ratio (r=0.143), BMI (r=0.125) and HOMA(ir) (r=0.192) (P<0.05 to P<0.001). The relationship of PLTP with HOMA(ir) was confined to subjects with the highest waist circumference and waist/hip ratio. In age- and sex-adjusted multiple linear regression models, waist circumference (β=0.158, P=0.025), but not BMI, predicted PLTP activity independently of HOMA(ir) (β=0.126, P=0.047). Furthermore, both waist and waist/hip ratio interacted positively with HOMA(ir) on PLTP activity (β=0.109, P=0.056 and β=0.156, P=0.034, respectively).
CONCLUSIONS: In non-diabetic subjects, both obesity and insulin resistance influence plasma PLTP activity, resulting in elevated plasma PLTP activity particularly with combined increases in obesity and insulin resistance. Higher PLTP activity could contribute to elevated cardiovascular risk in the presence of obesity and insulin resistance.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21481395     DOI: 10.1016/j.atherosclerosis.2011.03.021

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

Review 1.  Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism.

Authors:  John J Albers; Simona Vuletic; Marian C Cheung
Journal:  Biochim Biophys Acta       Date:  2011-06-28

2.  HDL size is more accurate than HDL cholesterol to predict carotid subclinical atherosclerosis in individuals classified as low cardiovascular risk.

Authors:  Eliane Soler Parra; Natalia Baratella Panzoldo; Vanessa Helena de Souza Zago; Daniel Zanetti Scherrer; Fernanda Alexandre; Jamal Bakkarat; Valeria Sutti Nunes; Edna Regina Nakandakare; Eder Carlos Rocha Quintão; Wilson Nadruz; Eliana Cotta de Faria; Andrei C Sposito
Journal:  PLoS One       Date:  2014-12-03       Impact factor: 3.240

3.  Comparison of frequency of insulin resistance in patients with chronic obstructive pulmonary disease with normal controls.

Authors:  Zareen Kiran; Numan Majeed; Bader Faiyaz Zuberi
Journal:  Pak J Med Sci       Date:  2015 Nov-Dec       Impact factor: 1.088

4.  Quantitative genomics of 30 complex phenotypes in Wagyu x Angus F₁ progeny.

Authors:  Lifan Zhang; Jennifer J Michal; James V O'Fallon; Zengxiang Pan; Charles T Gaskins; Jerry J Reeves; Jan R Busboom; Xiang Zhou; Bo Ding; Michael V Dodson; Zhihua Jiang
Journal:  Int J Biol Sci       Date:  2012-06-12       Impact factor: 6.580

5.  Metabolism of plasma cholesterol and lipoprotein parameters are related to a higher degree of insulin sensitivity in high HDL-C healthy normal weight subjects.

Authors:  Camila C Leança; Valéria S Nunes; Natália B Panzoldo; Vanessa S Zago; Eliane S Parra; Patrícia M Cazita; Matti Jauhiainen; Marisa Passarelli; Edna R Nakandakare; Eliana C de Faria; Eder C R Quintão
Journal:  Cardiovasc Diabetol       Date:  2013-11-22       Impact factor: 9.951

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.